Federal contract award
75N91018F00057
IGF::OT::IGF ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 561210 — Facilities Support Services |
| PSC | M1HA — OPERATION OF GOVERNMENT-OWNED CONTRACTOR-OPERATED (GOCO) R&D FACILITIES |
| Parent award / vehicle | HHSN261201500003I |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $9.2M |
| Current contract value | $9.2M |
| Potential contract value / ceiling | $9.2M |
| Start date | Jul 13, 2018 |
| Current end date | Mar 31, 2021 |
| Potential end date | Mar 31, 2021 |
| Latest award activity | Sep 17, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 17, 2025 | P00006 | $23.2K | FY26 UDO INITIATIVE - ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
| Mar 8, 2022 | P00005 | $0 | ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
| Jun 14, 2021 | P00004 | $0 | ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
| Nov 10, 2020 | P00003 | $192.7K | ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
| Jul 27, 2020 | P00002 | $0 | ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
| Sep 23, 2019 | P00001 | $1.6M | ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
| Jul 13, 2018 | 0 | $7.4M | IGF::OT::IGF ANTI-HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODY (BNABS) DRUG SUBSTANCE (DS) CLINICAL TRIAL MATERIAL PRODUCTION AND RELEASE |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.